The human α-defensin-derived peptide HD5(1–9) inhibits cellular attachment and entry of human cytomegalovirus

Publication date: Available online 21 March 2020Source: Antiviral ResearchAuthor(s): Rebecca Böffert, Ramona Businger, Hannes Preiß, Dirk Ehmann, Vincent Truffault, Claudia Simon, Natalia Ruetalo, Klaus Hamprecht, Patrick Müller, Jan Wehkamp, Michael Schindler
Source: Antiviral Therapy - Category: Virology Source Type: research

Related Links:

CONCLUSIONS: Cytokine gene polymorphisms IL-12B and IL-1B were found to be associated with an increased risk of infection in kidney transplants and IL-28B in liver transplant recipients. However, the small number and heterogeneity of studies limits the generalization of our results. Further research may lead to finding these associations in larger studies which perhaps improve the use of genetic testing and targeted antiviral therapy. This will further reduce the risk of viral infections associated with cytokine gene polymorphisms in post renal and liver transplant recipients. PMID: 32365304 [PubMed - as supplied by publisher]
Source: J Pharm Pharm Sci - Category: Drugs & Pharmacology Authors: Tags: J Pharm Pharm Sci Source Type: research
The routine use of cytomegalovirus immune globulin (CMV-Ig) to provide passive immunity to cytomegalovirus (CMV) in patients is not supported in published literature. International guidelines do not advocate for the use of CMV-Ig alone in thoracic transplant and provide only weak recommendations for its role in combination with antiviral therapy for prevention of CMV. The utilization of CMV-Ig incurs significant cost, and carries the potential for infusion related toxicities. Furthermore, in 2012, an international survey reported only 38 % of thoracic transplant centers utilized CMV-Ig as part of a universal prophylaxis protocol.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Tags: (1300) Source Type: research
This article describes the studies that have been conducted to date and emphasises that mortality after stem cell transplant (not attributed to CMV end-organ disease) has recently become the first proven indirect effect of CMV now that letermovir has significantly reduced non-relapse deaths.The implications for CMV vaccines are then discussed. Vaccines are already predicted to be highly cost-effective if they can reduce CMV end-organ disease. Health planners should now consider that cost effectiveness is likely to be enhanced further through reduction of the indirect effects of CMV. A prototype scheme for assessing this po...
Source: Antiviral Therapy - Category: Virology Source Type: research
Cytomegalovirus (CMV) infection continues to be a clinically relevant problem in allogeneic hematopoietic stem cell transplant recipients (allo-HSCT) [1]. Preemptive antiviral therapy (PET) triggered upon detection of CMV DNA in the blood compartment has long been the first-choice strategy for prevention of CMV disease in this setting [1]. How this strategy will be positioned in the management of CMV infection in the new era of letermovir prophylaxis [2,3] remains to be established. Neither is there consensus on the CMV DNA load threshold that should prompt initiation of PET, nor on whether this cut-off should be adapted a...
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research
An effective T cell response is necessary for the control of cytomegalovirus (CMV) reactivation after allogeneic stem cell transplant (alloBMT) - CMV is associated with significant morbidity, especially in patients (pts) who require recurrent episodes of antiviral therapy&those who develop associated end organ dysfunction (CMV disease). We sought to determine whether deep sequencing of T cell receptor beta (TRB) loci could identify&quantitate T cell clonotypes with specificity for CMV epitopes in the early post-alloBMT period and assess association with virus related outcomes.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Tags: 475 Source Type: research
Publication date: Available online 12 January 2020Source: Antiviral ResearchAuthor(s): Sunwen ChouAbstractCytomegalovirus (CMV) drug resistance mutation maps are updated with recent information for polymerase inhibitors, the terminase inhibitor letermovir and the UL97 kinase inhibitor maribavir. Newly mapped mutations and their phenotypes provide more detail on cross-resistance properties and suggest the need to expand the CMV gene regions covered in diagnostic testing. Next-generation deep sequencing technology offers a more sensitive, higher resolution view of emerging antiviral resistance and is recommended for use in c...
Source: Antiviral Therapy - Category: Virology Source Type: research
Publication date: Available online 12 January 2020Source: Antiviral ResearchAuthor(s): Islam T.M. Hussein, Jennifer Brooks, Terry L. BowlinAbstractHuman cytomegalovirus (HCMV) infections are widespread among the human population. Infection is persistent and mostly asymptomatic, except in immunocompromised individuals, particularly transplant patients, where significant morbidity and mortality can occur. Currently approved drugs for treating HCMV-related disease [including ganciclovir (GCV), valganciclovir (VGCV), cidofovir (CDV) and foscarnet (FOS)] all target the viral DNA polymerase and suffer from dose-limiting toxicity...
Source: Antiviral Therapy - Category: Virology Source Type: research
Conclusions: CMV colitis might be a rare cause of intractable diarrhea in immunocompetent children. Clinicians should be aware of the possibility of CMV colitis in patients with intractable diarrhea. PMID: 31917930 [PubMed - as supplied by publisher]
Source: Scandinavian Journal of Gastroenterology - Category: Gastroenterology Tags: Scand J Gastroenterol Source Type: research
ConclusionA delayed maturation of the auditory pathways should be considered when a mild/moderate isolated AN at birth is detected in cCMV infected infants. Prospective studies conducted on larger populations, and with a longer audiological follow-up, are needed to confirm our findings.
Source: Italian Journal of Pediatrics - Category: Pediatrics Source Type: research
This study was registered at www.clinicaltrials.gov as #NCT02156479. PMID: 31879324 [PubMed - as supplied by publisher]
Source: Haematologica - Category: Hematology Authors: Tags: Haematologica Source Type: research
More News: Antiviral Therapy | Cytomegalovirus | Virology